Trial Profile
The effect of an anti-VEGF drug on proliferative diabetic retinopathy complicated with diabetic macular edema.
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 09 Jun 2020
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema; Diabetic retinopathy
- Focus Therapeutic Use
- 08 Jun 2020 Status changed from recruiting to suspended.
- 09 Jun 2018 Status changed from not yet recruiting to recruiting.
- 06 Jun 2017 New trial record